Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
South Korean military plans to launch new division for future warfare
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
[DISCLOSURE] Komipharm International (041960) announced on Oct. 12 that its subsidiary in Australia has decided on a capital increase worth 18.9 billion won (US$16.82 million) through third-party allotment to finance its operations (2.06 billion won) and invest in facilities (16.89 billion won).
A total of 149,612 shares will be issued to Korea Insight Investment and 33 others. The issue price is 126,729 won per share.
By Yun Jeong-hyeon (clareyun@heraldcorp.com)
A total of 149,612 shares will be issued to Korea Insight Investment and 33 others. The issue price is 126,729 won per share.
By Yun Jeong-hyeon (clareyun@heraldcorp.com)
